- •Cenobamate is a useful adjunctive therapy for refractory focal-onset epilepsy in adult patients, but the safety and efficacy is yet to be established in the pediatric population.
- •We performed a retrospective analysis of a pediatric cohort of refractory focal-onset epilepsy receiving cenobamate as an adjunctive therapy.
- •We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events.
- •Cenobamate showed similar rates of efficacy, safety, and tolerability in the pediatric population when compared to adult data, even when used at maximum dose of 400 mg.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Management of the patient with medically refractory epilepsy.Expert Rev Neurother. 2009; 9: 1791-1802https://doi.org/10.1586/ern.09.114
- The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond [published correction appears in CNS Drugs. 2021 Aug 17].CNS Drugs. 2021; 35: 935-963https://doi.org/10.1007/s40263-021-00827-8
- The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ?.Epilepsia. 2021; 62: 596-614https://doi.org/10.1111/epi.16832
Shi LL, Bresnahan R, Martin-McGill K, Dong JC, Ni HJ, Geng JS Felbamate add-on therapy for drug-resistant focal epilepsy. Edited by Cochrane Epilepsy Group. Cochrane Database of Systematic Reviews, August 1, 2019. https://doi.org/10.1002/14651858.CD008295.pub5.
- Cenobamate: first approval.Drugs. 2020; 80: 73-78https://doi.org/10.1007/s40265-019-01250-6
- Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons.Eur J Pharmacol. 2019; 855: 175-182https://doi.org/10.1016/j.ejphar.2019.05.007
- Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate.Eur J Pharmacol. 2020; 879173117https://doi.org/10.1016/j.ejphar.2020.173117
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.Lancet Neurol. 2020; 19: 38-48https://doi.org/10.1016/S1474-4422(19)30399-0
- Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.Epilepsia. 2020; 61: 1099-1108https://doi.org/10.1111/epi.16525
- Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial.Epilepsy Curr. 2020; 20: 85-87https://doi.org/10.1177/1535759720903032
- Cenobamate, a sodium channel inhibitor and positive allosteric modulator of GABAA ion channels, for partial onset seizures in adults: a comprehensive review and clinical implications.Neurol Int. 2021; 13: 252-265https://doi.org/10.3390/neurolint13020026
- Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications.Epilepsia. 2021; 62: 3016-3028https://doi.org/10.1111/epi.17092
- Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development.Epilepsia. 2020; 61: 2365-2385https://doi.org/10.1111/epi.16726